Add objective developmental data to your Vineland assessments.
The Vineland gives your team valuable insight into how a child is functioning in everyday life. EarliPoint adds another perspective, providing objective developmental data collected directly from the child in a quick, child-friendly session.
Together, they give clinicians a fuller picture of a child’s development to consider during both evaluation and reassessment.
See it alongside your Vineland workflow
What EarliPoint adds to the Vineland
Different information. A more complete picture.
The Vineland helps your team understand how a child communicates, socializes, and navigates daily life, based on input from the people who know them best. EarliPoint offers a different perspective.
In a short session, eye-tracking technology directly measures the child’s social visual engagement. It doesn’t replace the Vineland—it adds another source of objective developmental data that clinicians can consider alongside the Vineland and the other information they already use.
| Area | Vineland-3 | EarliPoint (objective layer) |
|---|---|---|
| What it measures | Adaptive behavior in daily life | Objective indices of social, verbal, and nonverbal development |
| Method | Caregiver/teacher interview or rating | Automated eye-tracking biomarker |
| Input | Respondent recall and report | Direct, moment-by-moment measurement |
| Observer dependence | Moderate — varies with respondent and interviewer | Low — automated, observer-independent |
Proven Science
Decades of research. Breakthrough results.
EarliPoint is backed by more than 20 years of research into autism and social visual engagement.
The EarliPoint System is an FDA-cleared medical device designed to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder. Its research foundation includes large-scale clinical studies, peer-reviewed publications, and academic research conducted in collaboration with leading institutions.
Our research foundation includes:
-
Clinical Validation — Two large-scale, double-blind clinical studies
-
Peer Review — Findings published in the Journal of the American Medical Association (JAMA)
-
Academic Excellence — Research conducted in collaboration with Yale University and Emory University
DATE: September 5, 2023
Eye-Tracking-Based Measurement of Social Visual Engagement Compared with Expert Clinical Diagnosis of Autism.
DATE: September 5, 2023
Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism.
Common questions
No — and it isn’t designed to. The Vineland provides the adaptive, real-world picture in a standardized format payers recognize. EarliPoint adds an objective developmental data stream beside it. It complements, and never replaces, clinical judgment and established assessment practices.
The Vineland is standardized but report-based — it reflects caregiver recall, and profiles can vary with who reports and who administers. An objective measure adds a second, observer-independent stream, reducing reliance on any single source.
Trained staff administer it, and it’s a quick assessment; qualified clinicians interpret the results. It doesn’t add BCBA hours — it gives them back.
EarliPoint is FDA-cleared for children 16 through 95 months who are at risk based on concerns from a parent, caregiver, or healthcare provider — spanning the early-intervention window where progress documentation matters most.
See How EarliPoint Fits Alongside Your Vineland Assessments
Want to see what EarliPoint could add to the assessment process you already have? We’ll walk you through how it can fit into your current workflow and show you the objective developmental data your clinical team receives.
